C12N 9/6475
Interleukin 1-beta convertase-like enzymes
Official title: {Interleukin 1-beta convertase-like enzymes (3.4.22.10; 3.4.22.36; 3.4.22.63)}
C12N9/6475 (Interleukin 1-beta convertase-like enzymes) appears on 164 US grants and 160 published applications in this corpus.
Search patents in C12N- Granted patents
- 164
- Published applications
- 160
- Assignees
- 104
- Inventors
- 329
- Latest grant
- 23 Apr 2024
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1994 | 2 | 0 |
| 1995 | 1 | 0 |
| 1996 | 2 | 0 |
| 1997 | 3 | 0 |
| 1998 | 9 | 0 |
| 1999 | 13 | 0 |
| 2000 | 14 | 0 |
| 2001 | 13 | 2 |
| 2002 | 13 | 24 |
| 2003 | 18 | 28 |
| 2004 | 14 | 15 |
| 2005 | 7 | 9 |
| 2006 | 12 | 13 |
| 2007 | 7 | 8 |
| 2008 | 7 | 5 |
| 2009 | 2 | 11 |
| 2010 | 1 | 5 |
| 2011 | 2 | 4 |
| 2012 | 3 | 4 |
| 2013 | 1 | 2 |
| 2014 | 4 | 3 |
| 2015 | 4 | 6 |
| 2016 | 1 | 2 |
| 2017 | 1 | 3 |
| 2018 | 2 | 1 |
| 2019 | 1 | 3 |
| 2020 | 1 | 1 |
| 2021 | 2 | 5 |
| 2022 | 1 | 1 |
| 2023 | 2 | 3 |
| 2024 | 1 | 0 |
| 2025 | 0 | 1 |
| 2026 | 0 | 1 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Programmable protein circuits in living cells23 Apr 2024US 11,965,191 B2California Institute of Technology
- Modified T lymphocytes comprising a CD52 antibody-inducible caspase and methods of apoptosis7 Nov 2023US 11,806,365 B2Celgene Corporation
- Macrobrachium nipponense Cathepsin L gene, dsRNA thereof, and use thereof2 May 2023US 11,639,502 B2Freshwater Fisheries Research Center, Chinese Academy of Fishery Sciences
- Cysteine protease13 Dec 2022US 11,524,057 B2Hansa Biopharma AB
- Modified T lymphocytes comprising a BAFF antibody-inducible caspase and methods of apoptosis6 Apr 2021US 10,967,005 B2Celgene Corporation
- Compositions, systems, and methods for reducing adipose tissue23 Apr 2026US 2026/0109963 A1Oisin Biotechnologies, Inc.
- Synpoptosis circuits for programmable cell death control15 May 2025US 2025/0152743 A1
- Cysteine protease28 Sep 2023US 2023/0302100 A1Hansa Biopharma AB
- Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins11 May 2023US 2023/0142731 A1Genethon
- Orthogonal safety switches to eliminate genetically engineered cells23 Mar 2023US 2023/0085945 A1The Board of Trustees of the Leland Stanford Junior University
Most cited
By later US patents
- Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy129US 6,348,185 B1Washington University School of Medicine · 2002
- Anti-pathogen system and methods of use thereof79US 6,221,355 B1Washington University · 2001
- Modulation of apoptosis with bid71US 6,326,354 B1Washington University · 2001
- Galectin-11 polypeptides65US 6,605,699 B1Human Genome Sciences, Inc. · 2003
- Anti-pathogen system and methods of use thereof57US 6,645,501 B2Washington University · 2003